Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III obinutuzumab vs MMF in childhood-onset idiopathic nephrotic syndrome
jRCT2011220036Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of obinutuzumab in Idiopathic nephrotic syndrome (INS) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Percentage of participants with sustained complete remission at 1 year. Started Mar 2023; status: completed.
02
Drugs
obinutuzumab
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on jRCT2011220036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220036.